1. Scrip
  2. >>Business
  3. >>Strategy

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

 
• By Sten Stovall

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

Profile of a human head with a colorful symbol of neurons in the brain
• Source: Shutterstock

Renewed worries over H. Lundbeck AS's pipeline and prospects resurfaced amid news the Danish CNS specialist's antipsycotic drug Rexulti (brexpiprazole) did not meet the primary endpoint in treating bipolar I manic episodes in two global Phase III trials.

Analysts said the drug's failure in both advanced studies was unexpected and a negative blow to how investors view the stock, which is already under pressure from previous portfolio

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.